Filtered By:
Condition: Arrhythmia
Drug: Warfarin

This page shows you your search results in order of date. This is page number 19.

Order by Relevance | Date

Total 353 results found since Jan 2013.

Antiplatelet Therapy in Japanese Patients with Atrial Fibrillation without Oral Anticoagulants: Pooled Analysis of Shinken Database, J-RHYTHM Registry and Fushimi AF Registry
Atrial fibrillation (AF) is the most common cardiac arrhythmia and increases the risk of ischemic stroke. Oral anticoagulants (OAC) are effective for stroke prevention in patients with AF, and recent evidences have revealed the efficacy and safety of non-vitamin K antagonist OAC (NOAC) as well as warfarin. Although aspirin was shown to be inferior to warfarin or apixaban in preventing stroke [1,2], it is still prescribed to many AF patients in clinical practice [3–5]. This may be because physicians perceived it to be a safer and more convenient alternative to OAC.
Source: International Journal of Cardiology - April 22, 2015 Category: Cardiology Authors: Hisashi Ogawa, Masaharu Akao, Shinya Suzuki, Takeshi Yamashita, Ken Okumura, Hirotsugu Atarashi, Hiroshi Inoue Tags: Letter to the Editor Source Type: research

Uninterrupted Dabigatran versus Warfarin in the Treatment of Intracardiac Thrombus in Patients with non-Valvular Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice and increases the risk of thrombus in the left atrial appendage (LAA) which is strongly associated with an increased risk of ischemic stroke [1, 2]. Embolic strokes caused by AF are typically severe, more commonly disabling and fatal compared with strokes not associated with AF [1, 3]. Transesophageal echocardiography (TEE) is a sensitive method for intracardiac thrombus identification. When AF lasts for 2 days, atrial thrombi may take place in up to 14% patients on TEE examination; the prevalence of thrombus in AF patients varies from 10% ...
Source: International Journal of Cardiology - April 15, 2015 Category: Cardiology Authors: Li Hao, Jing-quan Zhong, Wei Zhang, Bing Rong, Fei Xie, Jun-tao Wang, Xin Yue, Zhao-tong Zheng, Qing Zhu, Yun Zhang Tags: Letter to the Editor Source Type: research

Stroke prevention with rivaroxaban in higher‐risk populations with atrial fibrillation
ConclusionsThese subgroup analyses demonstrate that the treatment effect for rivaroxaban vs. warfarin is broadly consistent across a wide range of patient groups, with respect to both efficacy and safety.
Source: International Journal of Clinical Practice - April 9, 2015 Category: Internal Medicine Authors: H.‐C. Diener, J. L. Halperin, K. Fox, G. J. Hankey Tags: Review Article Source Type: research

Non-Vitamin K Antagonist Oral Anticoagulants Do Not Increase Cerebral Microbleeds
Atrial fibrillation (AF) is a cardiac arrhythmia that frequently induces ischemic strokes. Nowadays, non-vitamin K antagonist oral anticoagulants (NOACs) have come into widespread use for cardiogenic embolism prevention in place of warfarin. Recently, cerebral microbleeds (CMBs) have been noticed for their potential implication in cerebral small vessel disease. We hypothesized that NOACs do not have an unfavorable influence over cerebral small vessels and investigated whether NOACs increase CMBs in AF patients in a prospective manner.
Source: Journal of Stroke and Cerebrovascular Diseases - April 3, 2015 Category: Neurology Authors: Tsukasa Saito, Yuichiro Kawamura, Nobuyuki Sato, Kohei Kano, Kae Takahashi, Asuka Asanome, Jun Sawada, Takayuki Katayama, Naoyuki Hasebe Source Type: research

Case 4–2015
ATRIAL FIBRILLATION (AF) is the most common cardiac arrhythmia in the world and is estimated to affect more than 3 million people in the United States, with a projected increase to more than 5 million people in the US by the year 2050.1 AF is an independent risk factor for stroke and is associated with a four- to five-fold increased risk of embolic stroke compared with those individuals without AF. Oral anticoagulation therapy with warfarin or other agents (dabigatran, apixaban) significantly reduces the risk of stroke in this population; however, anticoagulation carries inherent risks.
Source: Journal of Cardiothoracic and Vascular Anesthesia - March 18, 2015 Category: Anesthesiology Authors: Megan J. Lanigan, Mark A. Chaney, Sandeep Nathan, Atman P. Shah, Andrew J. Feider Tags: Case Conference Source Type: research

Left atrial thrombus formation and resolution during dabigatran therapy: A Japanese Heart Rhythm Society report
Conclusions LA thrombus developed in 4% of patients with AF receiving Dabi. Older patients with a higher CHADS2 score receiving a lower Dabi dosage were more likely to develop LA thrombus, which was resolved with a prolonged or increased dosage. A higher Dabi dosage may be more beneficial before ECV but prospective randomized studies would be needed to confirm these results.
Source: Journal of Arrhythmia - March 14, 2015 Category: Cardiology Source Type: research

Relation of growth differentiation factor-15 with CHADS-VASc score in Chinese patients with non-valvular atrial fibrillation
Atrial fibrillation (AF) is the most common sustained arrhythmia. AF significantly increases the risk of stroke, systemic thromboembolism and cardiac death. The refined CHA2DS2-VASc score includes additional risk factors and performs better than CHADS2 score in identifying patients who are truly low-risk patients. It is the recommended scheme for stroke risk stratification in patients with non-valvular AF [1]. In a recent substudy of the ARISTOTLE trial, Wallentin et al. [2,3] evaluated the prognostic role of growth differentiation factor-15 (GDF-15), a biomarker of oxidative stress and inflammation, in patients with AF re...
Source: International Journal of Cardiology - March 10, 2015 Category: Cardiology Authors: Tong Liu, Qingmiao Shao, Chee Yuan Ng, Jianping Zhao, Gang Xu, Yanmin Xu, Guangping Li Tags: Letter to the Editor Source Type: research

Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial Arrhythmia and Electrophysiology
Conclusions TTR, the standard measure of control of warfarin anticoagulation, depends on imputing daily INR values for the vast majority of follow-up days. Our TTR calculation method may better reflect the impact of warfarin dose changes than the Rosendaal approach. In the ROCKET AF trial, this dose change–based approach led to a modest increase in overall mean iTTR but did not materially affect the large inter-regional differences previously reported. Clinical Trial Registration URL: ClinicalTrials.gov. Unique identifier: NCT00403767.
Source: JAHA:Journal of the American Heart Association - March 3, 2015 Category: Cardiology Authors: Singer, D. E., Hellkamp, A. S., Yuan, Z., Lokhnygina, Y., Patel, M. R., Piccini, J. P., Hankey, G. J., Breithardt, G., Halperin, J. L., Becker, R. C., Hacke, W., Nessel, C. C., Mahaffey, K. W., Fox, K. A. A., Califf, R. M., for the ROCKET AF Investigators Tags: Arrhythmia and Electrophysiology Source Type: research

Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation
This article is protected by copyright. All rights reserved.
Source: Journal of Internal Medicine - March 1, 2015 Category: Internal Medicine Authors: Adrian M. Shields, Gregory Y. H. Lip Tags: Review Article Source Type: research

Prospective National Study of the Prevalence, Incidence, Management and Outcome of a Large Contemporary Cohort of Patients With Incident Non-Valvular Atrial Fibrillation Arrhythmia and Electrophysiology
Conclusions In the present study the prevalence and incidence of AF, stroke, and death were comparable to those reported in Europe and North America. The low use of anticoagulation calls for measures to increase adherence to current treatment recommendations in order to improve outcomes.
Source: JAHA:Journal of the American Heart Association - January 21, 2015 Category: Cardiology Authors: Haim, M., Hoshen, M., Reges, O., Rabi, Y., Balicer, R., Leibowitz, M. Tags: Arrhythmia and Electrophysiology Source Type: research

Risk of warfarin-associated intracerebral haemorrhage after ischaemic stroke is low and unchanged during the 2000s
Commentary on: Asberg A, Erisksson M, Henriksson KM, et al.. Warfarin-associated intracerebral hemorrhage after ischemic stroke. Stroke 2014;45:2118–20. Context Since its isolation during the early half of the 20th century from the mouldy hay responsible for ‘sweet clover disease’ in cattle, warfarin has become the most widely used oral anticoagulant.1 Indications include atrial fibrillation (AF), mechanical prosthetic valves and venous thromboembolism treatment.2 Warfarin reduces stroke risk in patients with AF by nearly two-thirds; AF accounts for 20% of ischaemic strokes, which tend to be more severe t...
Source: Evidence-Based Medicine - January 21, 2015 Category: Internal Medicine Authors: Ruland, S., Biller, J. Tags: Epidemiologic studies, Drugs: cardiovascular system, Stroke, Hypertension, Alcohol-related disorders, Drugs misuse (including addiction), Arrhythmias, Alcohol, Health education Aetiology/Harm Source Type: research

Utility of a Dedicated Pediatric Cardiac Anticoagulation Program: The Boston Children’s Hospital Experience
Abstract Congenital heart disease is the leading cause of stroke in children. Warfarin therapy can be difficult to manage safely in this population because of its narrow therapeutic index, multiple drug and dietary interactions, small patient size, high-risk cardiac indications, and lack of data to support anticoagulation recommendations. We sought to describe our institution’s effort to develop a dedicated cardiac anticoagulation service to address the special needs of this population and to review the literature. In 2009, in response to Joint Commission National Patient Safety Goals for Anticoagulation, Boston...
Source: Mammalian Genome - January 8, 2015 Category: Genetics & Stem Cells Source Type: research

Time trends of aspirin and warfarin use on stroke and bleeding events in Chinese patients with new-onset atrial fibrillation.
Conclusion: Aspirin use increased amongst newly diagnosed Chinese AF patients with no relationship to the patient's stroke or bleeding risk. Warfarin use was very low. Given the healthcare burden of AF and its complications, our study has major implications for healthcare systems in non-Western countries, given the global burden of this common arrhythmia. PMID: 25501045 [PubMed - as supplied by publisher]
Source: Chest - December 11, 2014 Category: Respiratory Medicine Authors: Guo Y, Wang H, Tian Y, Wang Y, Lip GY Tags: Chest Source Type: research

Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation.
This article is a review of the major studies of the NOACs. The clinical use of these drugs in patients with non-valvular atrial fibrillation is presented. PMID: 25470147 [PubMed - in process]
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - December 5, 2014 Category: Cardiology Tags: Cardiovasc Hematol Agents Med Chem Source Type: research

Antithrombotic Therapy After Acute Ischemic Stroke in Patients With Atrial Fibrillation Clinical Sciences
Conclusions— Contrary to current guidelines, 30% of patients with atrial fibrillation and recent IS are not prescribed any OAC therapy on discharge, whereas a further 30% are prescribed combination OAC and antiplatelet therapy. Combination OAC and antiplatelet therapy in patients at high cardiovascular risk requires evaluation in clinical trials, particularly with the newer OACs, given their more favorable risk–benefit ratio compared with warfarin.
Source: Stroke - November 24, 2014 Category: Neurology Authors: McGrath, E. R., Kapral, M. K., Fang, J., Eikelboom, J. W., Conghaile, A. O., Canavan, M., O'Donnell, M. J., on behalf of the Investigators of the Ontario Stroke Registry Tags: Secondary prevention, Acute Cerebral Infarction, Arrhythmias, clinical electrophysiology, drugs Clinical Sciences Source Type: research